-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target

Benzinga·09/11/2026 11:17:37
語音播報
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.